Matches in SemOpenAlex for { <https://semopenalex.org/work/W1980854517> ?p ?o ?g. }
- W1980854517 endingPage "275" @default.
- W1980854517 startingPage "265" @default.
- W1980854517 abstract "Metastasis associated protein 1 (MTA1) is a component of the nucleosome remodeling and deacetylating (NuRD) complex which mediates gene silencing and is overexpressed in several cancers. We reported earlier that resveratrol, a dietary stilbene found in grapes, can down-regulate MTA1. In the present study, we show that PTEN is inactivated by MTA1 in prostate cancer cells. Further, we show that resveratrol promotes acetylation and reactivation of PTEN via inhibition of the MTA1/HDAC complex, resulting in inhibition of the Akt pathway. In addition, we show that MTA1 knockdown is sufficient to augment acetylation of PTEN indicating a crucial role of MTA1 itself in the regulation of PTEN acetylation contributing to its lipid phosphatase activity. Acetylated PTEN preferentially accumulates in the nucleus where it binds to MTA1. We also show that MTA1 interacts exclusively with PTEN acetylated on Lys125 and Lys128, resulting in diminished p-Akt levels. Finally, using orthotopic prostate cancer xenografts, we demonstrate that both resveratrol treatment and MTA1 knockdown enhance PTEN levels leading to a decreased p-Akt expression and proliferation index. Taken together, our results indicate that MTA1/HDAC unit is a negative regulator of PTEN which facilitates survival pathways and progression of prostate cancer and that resveratrol can reverse this process through its MTA1 inhibitory function." @default.
- W1980854517 created "2016-06-24" @default.
- W1980854517 creator A5016571184 @default.
- W1980854517 creator A5018755451 @default.
- W1980854517 creator A5035302490 @default.
- W1980854517 creator A5036990231 @default.
- W1980854517 creator A5053853878 @default.
- W1980854517 date "2015-02-01" @default.
- W1980854517 modified "2023-10-17" @default.
- W1980854517 title "Resveratrol regulates PTEN/Akt pathway through inhibition of MTA1/HDAC unit of the NuRD complex in prostate cancer" @default.
- W1980854517 cites W1485099234 @default.
- W1980854517 cites W1512414376 @default.
- W1980854517 cites W1898126039 @default.
- W1980854517 cites W1977267072 @default.
- W1980854517 cites W1998038367 @default.
- W1980854517 cites W2003753117 @default.
- W1980854517 cites W2007353065 @default.
- W1980854517 cites W2017739035 @default.
- W1980854517 cites W2021647600 @default.
- W1980854517 cites W2025273529 @default.
- W1980854517 cites W2026901400 @default.
- W1980854517 cites W2032737825 @default.
- W1980854517 cites W2039139796 @default.
- W1980854517 cites W2046077454 @default.
- W1980854517 cites W2046234516 @default.
- W1980854517 cites W2047352825 @default.
- W1980854517 cites W2051023783 @default.
- W1980854517 cites W2051682149 @default.
- W1980854517 cites W2052433885 @default.
- W1980854517 cites W2052549908 @default.
- W1980854517 cites W2054020882 @default.
- W1980854517 cites W2055100889 @default.
- W1980854517 cites W2060739426 @default.
- W1980854517 cites W2070942270 @default.
- W1980854517 cites W2071643828 @default.
- W1980854517 cites W2074380974 @default.
- W1980854517 cites W2077520568 @default.
- W1980854517 cites W2077582389 @default.
- W1980854517 cites W2089412998 @default.
- W1980854517 cites W2090906911 @default.
- W1980854517 cites W2093108716 @default.
- W1980854517 cites W2102242260 @default.
- W1980854517 cites W2102950926 @default.
- W1980854517 cites W2103424665 @default.
- W1980854517 cites W2113261653 @default.
- W1980854517 cites W2114725617 @default.
- W1980854517 cites W2121244179 @default.
- W1980854517 cites W2123095951 @default.
- W1980854517 cites W2126336008 @default.
- W1980854517 cites W2129795601 @default.
- W1980854517 cites W2131234404 @default.
- W1980854517 cites W2132847329 @default.
- W1980854517 cites W2137423262 @default.
- W1980854517 cites W2144446057 @default.
- W1980854517 cites W2148416479 @default.
- W1980854517 cites W2151089147 @default.
- W1980854517 cites W2151581451 @default.
- W1980854517 cites W2152153043 @default.
- W1980854517 cites W2152988906 @default.
- W1980854517 cites W2154398220 @default.
- W1980854517 cites W2158626602 @default.
- W1980854517 cites W2159801541 @default.
- W1980854517 cites W2161810908 @default.
- W1980854517 cites W2171424206 @default.
- W1980854517 doi "https://doi.org/10.1016/j.bbamcr.2014.11.004" @default.
- W1980854517 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25447541" @default.
- W1980854517 hasPublicationYear "2015" @default.
- W1980854517 type Work @default.
- W1980854517 sameAs 1980854517 @default.
- W1980854517 citedByCount "103" @default.
- W1980854517 countsByYear W19808545172015 @default.
- W1980854517 countsByYear W19808545172016 @default.
- W1980854517 countsByYear W19808545172017 @default.
- W1980854517 countsByYear W19808545172018 @default.
- W1980854517 countsByYear W19808545172019 @default.
- W1980854517 countsByYear W19808545172020 @default.
- W1980854517 countsByYear W19808545172021 @default.
- W1980854517 countsByYear W19808545172022 @default.
- W1980854517 countsByYear W19808545172023 @default.
- W1980854517 crossrefType "journal-article" @default.
- W1980854517 hasAuthorship W1980854517A5016571184 @default.
- W1980854517 hasAuthorship W1980854517A5018755451 @default.
- W1980854517 hasAuthorship W1980854517A5035302490 @default.
- W1980854517 hasAuthorship W1980854517A5036990231 @default.
- W1980854517 hasAuthorship W1980854517A5053853878 @default.
- W1980854517 hasBestOaLocation W19808545171 @default.
- W1980854517 hasConcept C104317684 @default.
- W1980854517 hasConcept C119056186 @default.
- W1980854517 hasConcept C119157956 @default.
- W1980854517 hasConcept C121608353 @default.
- W1980854517 hasConcept C173396325 @default.
- W1980854517 hasConcept C185592680 @default.
- W1980854517 hasConcept C190283241 @default.
- W1980854517 hasConcept C2776816829 @default.
- W1980854517 hasConcept C2777609662 @default.
- W1980854517 hasConcept C2780192828 @default.
- W1980854517 hasConcept C502942594 @default.
- W1980854517 hasConcept C54355233 @default.